Form 4: Disc Medicine Director Mark Chin Granted 10,000 Stock Options

Disc Medicine, Inc. Director Mark Chin was granted 10,000 stock options with an exercise price of $50.86, vesting based on service and future company events.

Summary

• Mark Chin, a Director of Disc Medicine, Inc. (IRON), was granted 10,000 stock options.
• The options have an exercise price of $50.86 per share.
• The shares underlying the option will vest upon the earlier of the Company's 2026 annual meeting of stockholders or the one-year anniversary of the grant date (June 11, 2026).
• Vesting is contingent on Mr. Chin's continued service as a director.
• The options expire on June 10, 2035.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard practice that aligns management interests with shareholders, generally viewed as a neutral to slightly positive event as it incentivizes long-term performance without immediate dilution.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term company performance.
• The options have a long expiration date (June 10, 2035), providing ample time for potential value appreciation.

Risks

• The value of the stock options is dependent on the future market price of Disc Medicine, Inc. common stock, which is subject to market fluctuations and company performance.
• Vesting of the options is subject to the director's continued service, meaning the options could be forfeited if service ceases before vesting.

Future Outlook

The stock options granted to Director Mark Chin are forward-looking, with vesting contingent on future events such as the Company's 2026 annual meeting or the one-year anniversary of the grant date (June 11, 2026), subject to his continued service. The options themselves have a long-term expiration date of June 10, 2035, indicating a long-term incentive structure.

Industry Context

In the biotechnology and pharmaceutical industry, granting stock options to directors is a common practice to attract and retain experienced talent, align their interests with long-term shareholder value creation, and incentivize performance. This particular grant to a director of Disc Medicine, Inc., a company focused on hematologic and other severe diseases, is consistent with typical compensation structures in the sector.

Comparison to Industry Standards

• The grant of 10,000 stock options to a director is a standard form of equity compensation in the biotech industry, comparable to practices at companies like BioNTech SE or Moderna, Inc., which frequently use stock options or restricted stock units to compensate their board members and executives.
• The vesting schedule, tied to a one-year anniversary or the next annual meeting, is also a common structure designed to ensure continued service and align incentives with annual corporate milestones.
• The exercise price of $50.86, being the market price on the grant date, is standard for incentive stock options, ensuring that the director benefits only if the stock price appreciates from the grant date.

Corporate Governance

Related Party Transactions

• The grant of 10,000 stock options to Mark Chin, a Director of Disc Medicine, Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the director's interests with shareholders by incentivizing stock price appreciation. Potential future dilution if options are exercised, but this is a standard part of equity compensation.

Next Steps

• The stock options will vest upon the earlier of Disc Medicine's 2026 annual meeting of stockholders or June 11, 2026, subject to Mark Chin's continued service.

Key Dates

Keywords

Disc Medicine, IRON, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, Mark Chin, SEC Filing